142 related articles for article (PubMed ID: 31092203)
1. Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study.
Desalegn H; Aberra H; Berhe N; Medhin G; Mekasha B; Gundersen SG; Johannessen A
BMC Gastroenterol; 2019 May; 19(1):74. PubMed ID: 31092203
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia.
Desalegn H; Aberra H; Berhe N; Mekasha B; Stene-Johansen K; Krarup H; Pereira AP; Gundersen SG; Johannessen A
BMC Med; 2018 Dec; 16(1):234. PubMed ID: 30554571
[TBL] [Abstract][Full Text] [Related]
3. Five-year results of a treatment program for chronic hepatitis B in Ethiopia.
Desalegn H; Orlien SMS; Aberra H; Mamo E; Grude S; Hommersand K; Berhe N; Gundersen SG; Johannessen A
BMC Med; 2023 Sep; 21(1):373. PubMed ID: 37775742
[TBL] [Abstract][Full Text] [Related]
4. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa.
Aberra H; Desalegn H; Berhe N; Medhin G; Stene-Johansen K; Gundersen SG; Johannessen A
BMC Infect Dis; 2017 Jun; 17(1):438. PubMed ID: 28629395
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
[TBL] [Abstract][Full Text] [Related]
6. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
[TBL] [Abstract][Full Text] [Related]
7. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
[TBL] [Abstract][Full Text] [Related]
9. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia.
Aberra H; Desalegn H; Berhe N; Mekasha B; Medhin G; Gundersen SG; Johannessen A
J Hepatol; 2019 Jun; 70(6):1065-1071. PubMed ID: 30929749
[TBL] [Abstract][Full Text] [Related]
10. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
[TBL] [Abstract][Full Text] [Related]
11. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN
World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
Lim SG; Aung MO; Mak B; Sutedja D; Lee YM; Lee GH; Fernandes M; Low HC; Lai V; Dan YY
J Clin Gastroenterol; 2011 Oct; 45(9):818-23. PubMed ID: 21921845
[TBL] [Abstract][Full Text] [Related]
13. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis.
Lee SK; Song MJ; Kim SH; Lee BS; Lee TH; Kang YW; Kim SB; Song IH; Chae HB; Ko SY; Lee JD
World J Gastroenterol; 2017 Apr; 23(13):2396-2403. PubMed ID: 28428719
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
Yip TC; Lee HW; Wong VW; Wong GL; Tse YK; Lui GC; Ahn SH; Chan HL
J Gastroenterol Hepatol; 2020 Sep; 35(9):1610-1618. PubMed ID: 32032974
[TBL] [Abstract][Full Text] [Related]
16. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
17. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
18. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
Wong GL; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Wong VW
J Hepatol; 2018 Oct; 69(4):793-802. PubMed ID: 29758335
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.
Petersen J; Heyne R; Mauss S; Schlaak J; Schiffelholz W; Eisenbach C; Hartmann H; Wiese M; Boeker K; Loehr HF; John C; Leuschner M; Trautwein C; Felten G; Trein A; Krause W; Ruppert S; Warger T; Hueppe D
Dig Dis Sci; 2016 Oct; 61(10):3061-3071. PubMed ID: 26576555
[TBL] [Abstract][Full Text] [Related]
20. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
